Results 171 to 180 of about 1,388,675 (309)

The Saudi FDA drug evaluation timeline in comparison with international counterparts: a retrospective observational study. [PDF]

J Pharm Policy Pract
Algabbani AM, Hafiz R, AlWon B.
europepmc   +1 more source

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

Molecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy, Jana Löptien, Cornelia Coith, Afroditi Nanou, Katharina Hintelmann, Pinnschmidt Hans, Cordula Petersen, Klaus Pantel, Sabine Riethdorf, Kerstin Borgmann, Harriet Wikman   +10 more
wiley   +1 more source

Human Cardiac Organoids: Advances and Prospects from Construction to Preclinical Drug Evaluation. [PDF]

Cells
Chen M, Zhang T, Yang S, Niu Y, Ge Y, Chen Z, Zhang J, Pu Y, Gu Z, Liang G.   +9 more
europepmc   +1 more source

Live-cell imaging-based dynamic vascular formation assay for antivascular drug evaluation and screening. [PDF]

iScience, 2023
Li Z, Zhang H, Sun Y, Feng Z, Cui B, Han J, Li Y, Liu H, Sun T.   +8 more
europepmc   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Survival of ethnic and racial minority patients with multiple myeloma treated with newer medications

Blood Advances, 2018
E. Dianne Pulte, Lei Nie, Nicole Gormley, Kirsten B. Goldberg, Amy McKee, Ann Farrell, Richard Pazdur   +6 more
doaj   +1 more source

Criteria and regulatory considerations for the conditional approval of innovative antitumor drugs in China: from the perspective of clinical reviewers

Cancer Communications, 2023
Limin Zou, Yueli Qi, Yongling Jiang, Ling Tang, Yu Du, Boyuan Zhao, Yanzhe Sun, Meiyi Xiang, Jun Ma, Zhimin Yang   +9 more
doaj   +1 more source

Microbiota-gut-brain axis multi-organ chip construction and applications in drug evaluation. [PDF]

IMetaOmics
Tang Y, Chen H, Zhao Z, Kang X, Wang W, Dai K, Guo Y, Liang A, Luo A, Hao Z.   +9 more
europepmc   +1 more source

Establishment and large-scale validation of a three-dimensional tumor model on an array chip for anticancer drug evaluation. [PDF]

Front Pharmacol, 2022
Xiao RR, Jin L, Xie N, Luo P, Gao W, Tu P, Ai X.   +6 more
europepmc   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source